The natural history of type 2 diabetes. Implications for clinical practice (Q33752751)

29 July 2017

1 reference

title

The natural history of type 2 diabetes. Implications for clinical practice (English)

1 reference

29 July 2017

1 reference

Ramlo-Halsted BA

1

1 reference

PubMed ID

10523459

29 July 2017

Edelman SV

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

Primary Care: Clinics in Office Practice

29 July 2017

1 reference

29 July 2017

26

1 reference

29 July 2017

4

1 reference

29 July 2017

771-789

1 reference

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

The cardiovascular dysmetabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Impaired glucose tolerance in the U.S. population.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Natural history of beta-cell dysfunction in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970130-5

7 January 2021

10.1016/S0095-4543(05)70130-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10523459